Association of ticagrelor vs. clopidogrel with MACE in patients with ACS undergoing PCI

Findings show that ticagrelor reduces major adverse coronary events (MACE) in patients with acute coronary syndrome (ACS) while clopidogrel increases bleeding and dyspnea. Interested in whether the same is true for ACS patients treated with percutaneous coronary intervention (PCI), researchers in Canada designed a population-based cohort study.

Findings show that ticagrelor reduces major adverse coronary events (MACE) in patients with acute coronary syndrome (ACS) while clopidogrel increases bleeding and dyspnea. Interested in whether the same is true for ACS patients treated with percutaneous coronary intervention (PCI), researchers in Canada designed a population-based cohort study. The team pulled registry data from April 2012 through March 2016 for a sample population of 11,185 people who received outpatient prescriptions for ticagrelor or clopidogrel within 31 days following PCI. Based on 1-year followup, ticagrelor did not significantly lower the risk of MACE in ACS patients who underwent PCI, when compared with clopidogrel. At the same time, it was associated with a statistically significant increase in major bleeding and dyspnea. The research also discovered that MACE risk fell when patients adhered to their ticagrelor or clopidogrel regimens.